TMX Newsfile·2026-02-13 18:42Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities during the specified Class Period, highlighting potential misstatements and failures to disclose critical information regarding the company's regulatory submissions and product manufacturing [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Inovio - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing quality of its CELLECTRA device [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to these deficiencies [5]. - The lawsuit also states that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].